CVE:VPT VentriPoint Diagnostics (VPT) Stock Price, News & Analysis C$0.12 0.00 (0.00%) As of 07/21/2026 09:30 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartHeadlinesInsider TradesBuy This Stock About VentriPoint Diagnostics Stock (CVE:VPT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get VPT alerts:Sign Up Key Stats Today's RangeC$0.12▼C$0.1250-Day RangeC$0.10▼C$0.1552-Week RangeC$0.08▼C$0.19Volume10,370 shsAverage Volume125,726 shsMarket CapitalizationC$21.58 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Ventripoint Diagnostics Ltd., a medical device company, engages in the development and commercialization of diagnostic tools that monitor patients with heart disease worldwide. It offers Ventripoint Medical System (VMS), a medical imaging system that is used to generate three-dimensional models with critical volume and functional measurements of a patient's heart chambers. The company also provides VMS+ software, a 2D and 3D ultrasound models. In addition, it develops a suite of applications for various heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging, and cardiotoxicity in oncology patients. Ventripoint Diagnostics Ltd. is headquartered in Toronto, Canada. Read More Receive VPT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for VentriPoint Diagnostics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. VPT Stock News HeadlinesVentripoint and Ollie Hinkle Heart Foundation Partner to Expand Access to AI-Powered Heart Imaging for Children Living With Heart DiseaseJune 26, 2026 | finance.yahoo.comCardiac AI Diagnostics Stack Validation Wins Across Regulatory and Commercial FrontsMay 19, 2026 | tmcnet.comTSM just handed Trump's secretive AI project $100 billionTaiwan Semiconductor just committed another $100 billion to U.S. chip manufacturing - on top of $165 billion already pledged. Louis Navellier, who manages a $1.1 billion portfolio including $358 million in AI stocks, says this isn't about tariffs. Navellier believes TSM's move is smart money positioning ahead of a government AI supercomputing project he calls Golden Dawn - built at the same Tennessee site that housed the Manhattan Project. S&P 500 profits are tracking near 24% growth this quarter, with AI and chip demand leading the way.July 22 at 1:00 AM | InvestorPlace (Ad)A Toronto AI-Cardiac Diagnostics Company Just Cleared Three of the Hardest Validation Bars in MedtechMay 13, 2026 | markets.businessinsider.comVentripoint to Exhibit at the 59th Annual Meeting of the Association for European Paediatric and Congenital CardiologyMay 4, 2026 | finance.yahoo.comWhy Medtech Giants Are Quietly Paying Up for AI DiagnosticsApril 29, 2026 | tmcnet.comThe Quiet Rule Change Tilting $10B Toward Medtech's Most Validated PlatformsApril 29, 2026 | tmcnet.comThe Infrastructure Play Hiding in Plain Sight Across Cardiac CareApril 16, 2026 | financialpost.comFSee More Headlines VPT Stock Analysis - Frequently Asked Questions How have VPT shares performed this year? VentriPoint Diagnostics' stock was trading at C$0.14 on January 1st, 2026. Since then, VPT stock has decreased by 17.9% and is now trading at C$0.12. How do I buy shares of VentriPoint Diagnostics? Shares of VPT stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers. What other stocks do shareholders of VentriPoint Diagnostics own? Based on aggregate information from My MarketBeat watchlists, some other companies that VentriPoint Diagnostics investors own include Resverlogix (RVX), Meta Platforms (META), Sphere 3D (ANY), Aptose Biosciences (APTO), Antibe Therapeutics (ATE), Baytex Energy (BTE). Industry, Sector and Symbol Stock ExchangeCVE SectorMedical Industry Medical Devices Sub-IndustryN/A Current SymbolCVE:VPT CIKN/A Webwww.ventripoint.com Phone416-848-4156FaxN/AEmployees147,000Year FoundedN/AProfitability EPS (Trailing Twelve Months)C($0.02) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-C$5.25 million Net Margins-1,778.62% Pretax MarginN/A Return on Equity78.25% Return on Assets-136.72% Debt Debt-to-Equity Ratio-63.20 Current Ratio0.08 Quick Ratio6.67 Sales & Book Value Annual SalesC$179.93 thousand Price / Sales119.94 Cash FlowC$0.02 per share Price / Cash Flow5.53 Book ValueC($0.02) per share Price / Book-4.73Miscellaneous Outstanding Shares187,659,000Free FloatN/AMarket CapC$21.58 million OptionableNot Optionable Beta-0.29 10 Best Stocks to Own - Summer 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free Report This page (CVE:VPT) was last updated on 7/22/2026 by MarketBeat.com Staff. From Our PartnersAmerica’s answer to universal basic incomeRobert Kiyosaki, author of Rich Dad Poor Dad, is highlighting an income strategy he calls the Patriot Income P...Freedom Financial | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredBlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredTSM just handed Trump's secretive AI project $100 billionTaiwan Semiconductor just committed another $100 billion to U.S. chip manufacturing - on top of $165 billion a...InvestorPlace | SponsoredThe Starlink of EnergyA portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big...Monument Traders Alliance | SponsoredElon is about to dominate the biggest arms race in tech historyMicrosoft, Amazon, Alphabet, and Meta have collectively poured nearly $700 billion into AI infrastructure in 2...The Oxford Club | SponsoredIt all happens tonight.Tonight, trader Sean Allison is hosting a live session to walk through his Zero-Dollar Trade Advantage strateg...Trade Thirsty | SponsoredThe options guide that actually starts at the beginningMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...Base Camp Trading | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding VentriPoint Diagnostics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share VentriPoint Diagnostics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
